A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This trial will test the safety and efficacy of CF102 in patients with advanced liver cancer.
Successive groups of patients will be given higher doses of CF102 by mouth on a twice-daily
basis. Treatment will be assessed for adverse effects and for effects on the tumor.